May 23, 2022 new design drugs at low prices: psychostimulators, opiates, Psychedelics, Dissociatives, Cannabinoids and New Chemicals new chemical research, you can find new legal stimulants, new legal opiates, new legal dissociatives, legal psychedelics, legal marijuana.





Nitemazepam or also called 3-hydroxynimetazepam, is a designer benzodiazepine sedative drug, an analog of temazepam, with 7-nitro replaced with 7-chloro, and is a 3-hydroxy derivative as well as an active metabolite. This drug was first synthesized in the 1970s, but it had no medical use and was not commercially available. The full chemical name of nitemazepam is 3-hydroxy-1-methyl-7-nitro-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-2-one.

Little data is available at this time on the toxicological and other properties of the drug. It is intended for chemical studies in specially equipped laboratories.

You can buy Nitemazepam online right now from our manager as a designer drug for chemical research.

  • Nitemazepam
  • 3-hydroxynimetazepam
IUPAC 3-hydroxy-1-methyl-7-nitro-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-2-one
Formula C16H13N3O4
Molecular weight 311.292
CAS 842312-22-1
Appearance Powder
Purity ≥ 98 %

Nitemazepam and all other sedative designer drug on this website are for research and legal applications. Gidazepam is a designer drug with obvious physiological and psychoactive effects.

Side effects from Nitemazepam e are not known

Storage conditions: in a cool and dry place. Terms Nitemazepam , can last up to 2 years with proper storage conditions.


We would like to draw your attention to the fact that before you place an order on our website, we checked the legality of the necessary chemicals. The list of permitted chemicals you should know in your country. We did not send orders to Russia, Belarus, Hong Kong, Singapore. We would like you not to order prohibited chemicals in your country.

By purchasing chemical studies on you buy a chemical at a wholesale price and get a discount coupon on subsequent purchases on our website.

You may have missed